A detailed history of Nuveen Asset Management, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 162,649 shares of BGNE stock, worth $28.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
162,649
Holding current value
$28.7 Million
% of portfolio
0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $23.4 Million - $36.5 Million
162,649 New
162,649 $36.5 Million
Q3 2023

Nov 14, 2023

BUY
$179.87 - $225.13 $1.8 Million - $2.25 Million
10,000 Added 18.8%
63,200 $11.4 Million
Q2 2023

Aug 14, 2023

BUY
$178.3 - $266.78 $5.88 Million - $8.8 Million
33,000 Added 163.37%
53,200 $9.49 Million
Q1 2023

May 15, 2023

BUY
$215.53 - $274.5 $474,166 - $603,900
2,200 Added 12.22%
20,200 $4.35 Million
Q4 2022

Feb 14, 2023

SELL
$125.51 - $229.3 $10.5 Million - $19.2 Million
-83,516 Reduced 82.27%
18,000 $3.96 Million
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $627,104 - $962,257
4,758 Added 4.92%
101,516 $13.7 Million
Q2 2022

Aug 15, 2022

BUY
$121.11 - $216.05 $121,110 - $216,050
1,000 Added 1.04%
96,758 $15.7 Million
Q1 2022

May 16, 2022

BUY
$146.52 - $269.56 $3.79 Million - $6.98 Million
25,900 Added 37.08%
95,758 $18.1 Million
Q4 2021

Feb 14, 2022

BUY
$248.56 - $389.34 $1.66 Million - $2.6 Million
6,666 Added 10.55%
69,858 $18.9 Million
Q3 2021

Nov 12, 2021

BUY
$249.6 - $403.14 $758,284 - $1.22 Million
3,038 Added 5.05%
63,192 $22.9 Million
Q2 2021

Aug 16, 2021

BUY
$292.75 - $367.01 $1.6 Million - $2 Million
5,462 Added 9.99%
60,154 $20.6 Million
Q1 2021

May 17, 2021

BUY
$260.64 - $382.12 $831,441 - $1.22 Million
3,190 Added 6.19%
54,692 $19 Million
Q4 2020

Feb 16, 2021

SELL
$221.31 - $316.61 $1.61 Million - $2.31 Million
-7,287 Reduced 12.4%
51,502 $13.3 Million
Q3 2020

Nov 16, 2020

SELL
$189.18 - $286.44 $2.97 Million - $4.5 Million
-15,694 Reduced 21.07%
58,789 $16.8 Million
Q2 2020

Aug 14, 2020

BUY
$123.9 - $195.41 $3.17 Million - $5 Million
25,583 Added 52.32%
74,483 $14 Million
Q1 2020

May 14, 2020

SELL
$121.84 - $173.19 $840,696 - $1.2 Million
-6,900 Reduced 12.37%
48,900 $6.02 Million
Q4 2019

Feb 14, 2020

SELL
$115.78 - $208.34 $1.24 Million - $2.24 Million
-10,745 Reduced 16.15%
55,800 $9.25 Million
Q3 2019

Nov 14, 2019

SELL
$120.61 - $148.29 $590,989 - $726,621
-4,900 Reduced 6.86%
66,545 $8.15 Million
Q2 2019

Aug 15, 2019

BUY
$113.99 - $146.86 $8.14 Million - $10.5 Million
71,445 New
71,445 $8.86 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.